Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

BACKGROUND: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hescheler, Daniel A., Plum, Patrick S., Zander, Thomas, Quaas, Alexander, Korenkov, Michael, Gassa, Asmae, Michel, Maximilian, Bruns, Christiane J., Alakus, Hakan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305081/
https://www.ncbi.nlm.nih.gov/pubmed/32107691
http://dx.doi.org/10.1007/s10120-020-01045-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305081/
https://www.ncbi.nlm.nih.gov/pubmed/32107691
http://dx.doi.org/10.1007/s10120-020-01045-9

Ejemplares similares